Crestline Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001536054

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 3 positions · Total reported value $53.48M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Crestline Management, L.P. disclosed 3 equity positions with a combined reported value of $53.48M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were DNLI ($49.14M), SANA ($2.64M), EGHT ($1.69M). By sector, the heaviest allocations are Health Care 96.8%, Technology 3.2%.

Versus the prior quarter, Crestline Management, L.P. opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Crestline Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Crestline Management, L.P., based in Fort Worth, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 3 positions worth $53.48M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: FORT WORTH, TX, United States
  • SEC registration: 801-61607 (status: Approved), registered 2002-12-02
  • Regulatory AUM (Form ADV): $22.51B as of 2026-08-28
  • Client mix (by RAUM): pension and profit-sharing plans 94%, sovereign wealth funds 5%
  • Manages 37 private funds, of which 30 hedge funds
  • Website: crestlineinvestors.com

Portfolio Structure

  • 3 positions · $53.48M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: DNLI (DENALI THERAPEUTICS INC) at 91.9%
  • Average position size: $17.83M

Sector Tilt

  • Health Care 96.8%
  • Information Technology 3.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 reduced
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Crestline Management's reduction in DENALI THERAPEUTICS INC suggests a cautious stance towards the healthcare sector, possibly reflecting market concerns or a strategic shift in sector preferences. 2. Key Moves: - Reduction: Crestline sold off 1.9 million shares of DENALI THERAPEUTICS INC, representing a 13.6% decrease from the previous quarter. This significant reduction in holdings indicates a change in strategy or concerns about the company's prospects. - Hold: The fund maintained its positions in SANA BIOTECHNOLOGY INC and 8X8 INC NEW, indicating a belief in their long-term potential or a lack of compelling reasons to adjust these holdings. 3. Portfolio Structure: - Passive/Active: The information provided does not indicate whether the fund's approach is passive or active. However, the significant reduction in one position and the holding of others suggests a level of active management. - Sector Bias: The portfolio shows a bias towards healthcare, with two out of the top three holdings in this sector. - Risk Appetite: The reduction in DENALI THERAPEUTICS INC could suggest a lower risk appetite, as the fund appears to be trimming exposure to potentially volatile healthcare stocks. 4. Per-Holding One-Liner: - DNLI (DENALI THERAPEUTICS INC): Develops and commercializes therapies for rare genetic disorders; unverified - SANA (SANA BIOTECHNOLOGY INC): Focuses on developing treatments for neurological disorders; unverified - EGHT (8X8 INC NEW): Provides cloud communications services; unverified 5. One-Sentence Style Summary: Crestline Management rebalanced its portfolio in Q2 2026, reducing exposure to DENALI THERAPEUTICS INC while holding steady in other healthcare and technology holdings, reflecting a cautious approach with a preference for healthcare and cloud communication sectors.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 96.8%
Technology 3.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.91M $49.14M 91.90%
91.90%
Reduce
2 755.74K $2.64M 4.93%
4.93%
Hold
3 990.85K $1.69M 3.17%
3.17%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 100% R 100% F1 100% (modelled on 2026-Q1; 3/10 hit)

Low-confidence forecast This fund replaces about 39% of its Top-10 each quarter and backtests at F1 64% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 63% · recall 65% · F1 64% · avg rank error 2.3 · Top-10 turnover 39%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 20% 20% 20% DNLI · IWM · M · ET · FR · QQQ · ACA · NI · AQN · AIG DNLI · SANA · SPY · ASML · NI · TSM · KMB · CSTM · PCG · ETR
2024-Q2 40% 40% 40% DNLI · SANA · SPY · ASML · TSM · NI · PCG · KMB · ETR · CSTM IVV · DNLI · NVDA · IWM · AAPL · LW · TSM · SANA · KMB · AQN
2024-Q3 30% 30% 30% IVV · DNLI · NVDA · AAPL · LW · IWM · TSM · SANA · AQN · NI SPY · DNLI · NVDA · CRM · AA · AVGO · COHR · NSC · TSM · EVRG
2024-Q4 30% 30% 30% SPY · DNLI · NVDA · CRM · AVGO · COHR · AA · NSC · EVRG · ADBE IVV · NVDA · DNLI · QQQ · SPY · AMZN · GOOGL · JNJ · CSCO · MSFT
2025-Q1 10% 33% 15% IVV · NVDA · QQQ · DNLI · SPY · AMZN · GOOGL · JNJ · CSCO · MSFT DNLI · SANA · EGHT
2025-Q2 100% 100% 100% DNLI · SANA · EGHT DNLI · SANA · EGHT
2025-Q3 100% 100% 100% DNLI · SANA · EGHT DNLI · SANA · EGHT
2025-Q4 100% 100% 100% DNLI · SANA · EGHT DNLI · SANA · EGHT
2026-Q1 100% 100% 100% DNLI · SANA · EGHT DNLI · SANA · EGHT
2026-Q2 ★ 100% 100% 100% DNLI · SANA · EGHT DNLI · SANA · EGHT

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Crestline Management, L.P. buy in 2026-Q2?

In its 2026-Q2 13F filing, Crestline Management, L.P. reported 3 equity positions worth $53.48M in aggregate; its largest disclosed positions were DNLI ($49.14M), SANA ($2.64M), EGHT ($1.69M).

How large is Crestline Management, L.P.'s portfolio?

Crestline Management, L.P. reported $53.48M of long equity holdings across 3 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Crestline Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/crestline-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →